• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,739 shares, decreasing direct ownership by 0.77% to 354,330 units (SEC Form 4) (tax liability)

    5/8/26 5:00:23 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Connaughton Alan B.

    (Last)(First)(Middle)
    2800 DISCOVERY DR.

    (Street)
    ORLANDO FLORIDA 32826

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    LENSAR, Inc. [ LNSR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Operating Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    05/06/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock05/06/2026F2,739(1)D$5.385354,330D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units.
    /s/ Nicholas T. Curtis, attorney-in-fact05/08/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    4/1/2026$10.00Hold → Buy
    Lake Street
    3/18/2026$10.00Neutral → Buy
    BTIG Research
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR® Reports First Quarter 2026 Results and Provides Business Update

    7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre

    5/8/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® to Report First Quarter 2026 Results on May 8, 2026

    ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra

    4/30/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

    3/31/26 6:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENSAR upgraded by Lake Street with a new price target

    Lake Street upgraded LENSAR from Hold to Buy and set a new price target of $10.00

    4/1/26 9:08:15 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR upgraded by BTIG Research with a new price target

    BTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00

    3/18/26 8:19:03 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    SEC Form S-8 filed by LENSAR Inc.

    S-8 - LENSAR, Inc. (0001320350) (Filer)

    6/2/26 4:33:20 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events

    8-K - LENSAR, Inc. (0001320350) (Filer)

    5/29/26 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by LENSAR Inc.

    SCHEDULE 13G/A - LENSAR, Inc. (0001320350) (Subject)

    5/14/26 4:58:58 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,739 shares, decreasing direct ownership by 0.77% to 354,330 units (SEC Form 4) (tax liability)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:23 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4) (for withholding tax)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:25 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,350 shares, decreasing direct ownership by 0.77% to 174,609 units (SEC Form 4) (tax withholding)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:20 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR® Reports First Quarter 2026 Results and Provides Business Update

    7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre

    5/8/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® to Report First Quarter 2026 Results on May 8, 2026

    ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra

    4/30/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

    3/31/26 6:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care